RE:RE:RE:RE:What is (or may be) changing over the next 2 -3 weeks ?Accountprince wrote: Great response MM. I too feel that the likely deal will be with Baxter for the appetizer, main, dessert, drinks, fine wines and other libations. I also think that as the dinner progresses and Baxter is in awe of the feast they will potentially decide to pick up everything during the dinner. In fact they may have made that arrangement already - we shareholders don't know.
I do find it curious that - with the lack of disclosure of the full Baxter deal - heavily redacted - that management and governance have been able to deal in both shares and warrants for almost two years now. I always thought that securities laws precluded insiders from dealing until such time as all material news and events have been disclosed to all and its a level playing field from an information perspective for all parties.
The Baxter information must be material as why would it be hidden if minor or incidental? And if it had been disclosed would the share price have gone from $0.80 per share to around $0.20 per share now? Could it have gone much higher than the $0.80 per share on that information?
The feast that is being quietly prepared could best be described as a Michelin 2 star gourmet offering. The problem is that you pretty much have to be invited to attend the restaurant much less see the menu (unless you stumble across it as a few dozen investors have, and they can't by law, turn you away)
I think that as far as disclosures go, they have their lawyer on speed dial. The name of the game appears to be absolute minimum disclosure, particularly south of the border (or internationally fo that matter). It is my opinion this is likely the number one reason the US listing consideration (talk) keeps getting kicked down the road. The SEC has more and sharper teeth and would likely require more investor disclosure, or at least they migth have a different viewpoint on what is material.
I have no doubt that with a more active IR, more open Mgt., non dirt level OTC listing in the US, we could/should be trading at $ 1 - $ 2. Simply based on comparable companies (and what valuations they achieve with far less), the trial status and parameters, the lack of compatetion, the multi-trick nature of the offering, etc. . Add in some excitement surrounding the potential to help Covid-19 patients and we coudl be $ 2-$ 3 (pre FDA ruling). IMHO.